Additionally, Pan et al. had found that Bcl-2 inhibition and p53 activation could overcome apoptosis resistance and induce synthetic lethality in AML models.441 In phase II clinical trial, the safety and early efficacy of idasanutlin in combination with ABT-199 in young patients with neuroblastoma, AML, and ALL were evaluated (NCT04029688). Here, TP53 is linked to acute myeloid leukemia.